Skip to content
5 months \u00b7 classroom

Regulatory Affairs Course in Pune

iLearn CRI's 5-month Regulatory Affairs course in Pune covers CDSCO, USFDA, EMA submissions, eCTD, drug approval pathways, post-marketing compliance — taught by practicing regulatory professionals with placement support.

Duration
5 months
Mode
classroom
Fees
\u20b90.8L

Why regulatory affairs is one of the most stable careers in pharma

Regulatory affairs is the discipline of getting drugs approved and keeping them on the market. It is the bridge between the science of drug development and the laws that govern its marketing — and for pharma graduates with patience for detail and a strategic mindset, it is one of the most stable and well-compensated career paths available.

The demand is structural. Every drug a pharma company markets requires regulatory work for its entire commercial life: initial approval, post-approval changes, label updates, periodic safety updates, renewal, and eventually withdrawal. Indian generics exporters file thousands of ANDAs, DMFs, and dossiers every year, and Pune is at the centre of this ecosystem.

For B.Pharm, M.Pharm, and life-sciences graduates, regulatory affairs offers steady demand, structured progression, deep specialisation pathways (eCTD publishing, DMF, CMC strategy), and a strong long-term compensation curve.

What does a regulatory affairs professional actually do

The work depends heavily on the company and product, but most early-career regulatory affairs roles involve a mix of:

Regulatory strategy. Choosing the right approval pathway for a product (NDA vs ANDA vs 505(b)(2); centralised vs MRP in EU), assessing market entry timelines, and advising the development team on regulatory implications of formulation or trial design choices.

Dossier preparation. Compiling Module 1 (regional administrative), reviewing Modules 2–5 (clinical, nonclinical, quality summaries and details), and ensuring the submission is complete, internally consistent, and meets format requirements (eCTD validation passes, no broken references, correct hyperlinks).

Authority interactions. Drafting responses to deficiency letters, preparing for pre-submission meetings, managing variation submissions for post-approval changes, and shepherding the product through inspections.

Lifecycle management. Once approved, products generate constant regulatory work — annual reports, label changes, manufacturing site additions, packaging updates. This is where most regulatory affairs professionals spend the bulk of their time.

The work compounds. Every dossier you compile teaches you the patterns of the next one. Senior regulatory professionals (5+ years) operate strategically — choosing pathways, sequencing submissions across markets, defending positions in front of regulators.

The Pune regulatory affairs market in 2026

Pune is one of India’s strongest cities for regulatory affairs careers, particularly for generics, biosimilars, and CRO regulatory consulting. Major employers:

  • Cipla — large regulatory team handling US, EU, and emerging markets across 200+ products
  • Sun Pharma — significant Pune regulatory operations supporting global filings
  • Lupin — strong US generics regulatory team with active ANDA filings
  • Glenmark — diversified portfolio with active US and EU filings
  • Wockhardt — regulatory team focused on biosimilars and complex generics
  • Mylan / Viatris — large regulatory operations
  • Emcure — Pune-headquartered with major regulatory team
  • Syngene, Veeda, Lambda — CRO regulatory affairs and consulting services
  • Specialist regulatory boutiques — focused consulting practices

Salaries scale predictably: ₹3.5–4.5 LPA at entry, ₹5–7 LPA in eCTD publishing roles, ₹6–8.5 LPA in DMF specialisation, ₹9–14 LPA at senior associate or specialist level (3–5 years), and ₹16–28 LPA at manager level (7+ years).

What this course teaches

The 5-month curriculum is built around how Pune regulatory affairs teams actually work, with the depth required to be productive from day one in an entry-level role.

The first month builds foundations and the Indian regulatory framework — Drugs and Cosmetics Act, Schedule Y, the New Drugs and Clinical Trials Rules 2019, CDSCO organisation and SUGAM portal, and the practical workflow for an Indian generics filing.

Months two and three cover USFDA and European regulatory affairs in depth — IND/NDA/ANDA pathways, EMA centralised vs decentralised procedures, EU Clinical Trials Regulation, MHRA post-Brexit changes, and the strategic differences that drive market-by-market decisions.

Month four is CTD and eCTD submissions — the heart of regulatory work. You compile sections of a sample dossier, learn the lifecycle of submissions (initial, supplements, variations), get hands-on with Module 1 preparation, and use industry tools like Lorenz docuBridge or GlobalSubmit at an introductory level.

Month five covers post-approval lifecycle management, GMP and inspections, ICH Q-series quality framework, and intensive placement preparation. You walk through Form 483 response strategies, draft a sample variation submission, and complete the regulatory portion of a sample DMF.

Why graduates choose this regulatory affairs course

Most regulatory affairs courses in India are taught by academics with limited active regulatory practice. The curriculum tends to lag current regulations (especially EU CTR and US user-fee changes), and students leave without knowing how a real eCTD submission is built.

We rebuilt the curriculum around how Pune regulatory teams actually work. Our faculty includes:

  • A Senior Regulatory Affairs Manager with 12+ years of US and EU generics filings, who teaches the dossier compilation and strategy modules
  • A Regulatory Publishing Specialist with 5+ years on eCTD tools (Lorenz, GlobalSubmit) at a top-10 Pune generics company
  • A CDSCO regulatory consultant with active SUGAM filings and pre-submission meeting experience

These instructors teach from current submissions and live regulatory issues — not from textbook examples that are 5–10 years out of date.

Placement support for regulatory affairs roles

Regulatory affairs hiring is technically tested at most employers — you will face questions about CTD module structure, recent regulatory updates, and pathway selection in interviews. Our placement preparation addresses this:

Resume calibration. We rewrite resumes to surface specific submission types (ANDA, DMF, variation), regulatory tool exposure (eCTD platforms), and any quantifiable regulatory work — the exact signals regulatory hiring managers screen for.

Mock interviews with practicing regulatory professionals. Three rounds: technical (CTD structure, pathway selection, current updates), scenario-based (deficiency response, strategic choice questions), and behavioural. Every interview is conducted by a current regulatory professional at a Pune company.

Direct introductions. Our placement team works with 30+ regulatory employers across Pune. Top performers — particularly those who can demonstrate familiarity with current submissions — are introduced directly to regulatory hiring managers.

Internal-move support. Many of our students are existing pharma professionals (production, QA, formulation) seeking regulatory specialisation. We coach on the internal-transition conversation, including how to position the upskilling to your current employer for an internal move.

Apply for the next batch

Regulatory affairs batches begin every quarter at our Wakad campus, with batch sizes capped at 30 students for adequate hands-on dossier work. The course runs weekday evenings and Saturdays, designed to fit around current employment. Reach out on WhatsApp to discuss your background and the next intake batch.

Curriculum

What you\u2019ll learn, module by module.

  1. 01 Foundations of Regulatory Affairs
    • Drug development lifecycle from a regulatory lens
    • Major regulatory authorities: CDSCO, USFDA, EMA, MHRA, PMDA, NMPA
    • Career pathways in regulatory affairs
    • Indian and global regulatory landscape in 2026
    • Regulatory intelligence — staying current with changing guidance
  2. 02 Indian Regulatory Framework — CDSCO Deep Dive
    • Drugs and Cosmetics Act, 1940 and key rules
    • New Drugs and Clinical Trials Rules, 2019
    • Schedule M, Schedule Y, Schedule D
    • CDSCO organisation: SUGAM portal, Form 44, Form 45
    • State drug controllers and zonal offices
    • Approval pathways: new drug, biosimilar, generic
    • Import licences (Form 10, Form 11, Form 12-AA)
  3. 03 USFDA Regulatory Affairs
    • FDA structure: CDER, CBER, CDRH, CFSAN
    • 21 CFR overview
    • IND, NDA, ANDA, BLA pathways
    • Pre-IND, end-of-Phase 2, Pre-NDA meetings
    • Orange Book and patent strategy
    • Hatch-Waxman and 505(b)(2) pathways
    • User fees: PDUFA, GDUFA, BsUFA
    • Inspections: PAI, GMP audits, FDA Form 483
  4. 04 European Regulatory Affairs
    • EMA structure: CHMP, PRAC, CMDh
    • Marketing Authorisation Procedures: Centralised, Decentralised, MRP, National
    • EU Clinical Trials Regulation (CTR 536/2014)
    • PSUSA and EU PV reporting
    • Variation procedures (Type IA, IB, II)
    • MHRA post-Brexit divergence
  5. 05 CTD & eCTD Submissions
    • Common Technical Document (CTD) — Modules 1–5 in depth
    • Module 1: regional administrative information
    • Module 2: quality, nonclinical, clinical summaries
    • Modules 3–5: quality, nonclinical, clinical detail
    • eCTD lifecycle: initial submission, sequence numbering, validation
    • Tools: Lorenz docuBridge, ExtedoEURS, GlobalSubmit overview
    • Hands-on dossier compilation exercises
  6. 06 Drug Master Files & Active Substance
    • DMF types I–V (US perspective)
    • ASMF (Active Substance Master File) — EU
    • CEP (Certificate of Suitability)
    • DMF deficiency response strategies
  7. 07 Post-Approval & Lifecycle Management
    • Post-approval changes — variation classification
    • Annual reports and PADERs
    • Labelling and product information updates
    • Risk Evaluation and Mitigation Strategies (REMS)
    • Pharmacovigilance regulatory interface
    • Renewal and re-registration
  8. 08 Quality, GMP & Inspections
    • ICH Q-series (Q7, Q8, Q9, Q10, Q11, Q12)
    • GMP inspections: USFDA, EU GMP, Schedule M
    • Audit response and CAPA management
    • Form 483 and Warning Letter responses
  9. 09 Career Preparation & Placements
    • Resume preparation for regulatory roles
    • Mock interviews with practicing regulatory professionals
    • Pune pharma & regulatory consulting landscape
    • Direct hiring partner introductions
Career outcomes

Roles graduates step into.

  • Regulatory Affairs Associate (Trainee)
    Avg. CTC ₹ 3.5–4.5 LPA
  • Regulatory Affairs Associate
    Avg. CTC ₹ 4.5–6.5 LPA
  • Regulatory Publishing Specialist (eCTD)
    Avg. CTC ₹ 5.0–7.0 LPA
  • DMF Specialist
    Avg. CTC ₹ 6.0–8.5 LPA
  • Senior Regulatory Affairs (3-5 yrs)
    Avg. CTC ₹ 9.0–14.0 LPA
  • Regulatory Affairs Manager (7+ yrs)
    Avg. CTC ₹ 16.0–28.0 LPA
Placements

Where careers actually start.

Our placement record reflects what most institutes don\u2019t measure: not just where you start, but how fast you grow.

Alumni placed across pharma
500+

Alumni placed across pharma and CROs

Average starting CTC for
₹4.2L

Average starting CTC for graduates

Placement rate within 6
92%

Placement rate within 6 months of completion

Pharma & CRO hiring
50+

Pharma & CRO hiring partners in Pune

FAQ

Questions about the Regulatory Affairs

Can\u2019t find your answer? Reach out on WhatsApp\u2014we usually reply within an hour during business days.

Ask on WhatsApp \u2192
Is regulatory affairs a good career after B.Pharm?

Regulatory affairs is one of the most stable and well-paid career paths in pharma for B.Pharm graduates. It pays competitively (₹3.5–4.5 LPA at entry, scaling to ₹9–14 LPA at senior level), is heavily process-driven, and rewards specialisation deeply — an experienced eCTD publisher or DMF specialist commands strong premiums. The work also offers global mobility because regulatory frameworks (CTD, ICH guidelines) are largely harmonised internationally.

What is the difference between CDSCO and USFDA regulations?

CDSCO (India) and USFDA (United States) regulate drug approval and marketing in their respective markets, but the frameworks differ. USFDA uses 21 CFR with structured pathways (IND, NDA, ANDA, BLA), an electronic submission requirement (eCTD), and detailed user-fee programs. CDSCO operates under the Drugs and Cosmetics Act and the New Drugs and Clinical Trials Rules 2019, uses the SUGAM portal for submissions, and has zonal offices that handle regional matters. Indian generics exporters must comply with both — and many Pune regulatory professionals work both systems daily.

Will I learn eCTD in this course?

Yes. eCTD is the standard submission format for USFDA, EMA, MHRA, and many other authorities, and it is increasingly required for CDSCO submissions. The course includes hands-on dossier compilation exercises, sequence numbering, validation, and an overview of major eCTD tools (Lorenz docuBridge, GlobalSubmit). You will compile a sample Module 1 and walk through a complete dossier structure under instructor guidance.

Can I do regulatory affairs alongside my current pharma job?

Yes. The course runs weekday evenings (6–9 PM) and full Saturdays, designed for working pharma professionals who want to specialise in regulatory without leaving their current role. Many of our placements are internal moves — production or QA professionals who upskill into regulatory roles within the same company at a higher CTC.

Who hires regulatory affairs professionals in Pune?

Pune's regulatory affairs employer base is dense: Cipla, Sun Pharma, Lupin, Glenmark, Wockhardt, Mylan, Emcure, and several mid-sized generics exporters all have regulatory teams. CROs (Syngene, Veeda, Lambda, ICON) hire regulatory writers and consultants. Specialist regulatory consultancies (Lambda Therapeutic Research's RA division, smaller boutiques) also hire steadily. Pune is one of India's strongest cities for regulatory affairs careers, particularly for generics and biosimilars work.

How is regulatory affairs different from medical writing?

Both involve writing, but the focus differs. Regulatory affairs is about strategy and submissions — choosing the right pathway, preparing the dossier, interacting with regulators, and managing the product lifecycle. Medical writing is about producing the clinical and scientific content within submissions (CSRs, protocols, patient narratives). Many regulatory professionals also write portions of their submissions, but the core skill is regulatory strategy, not just writing. Regulatory roles also pay slightly higher at the senior level due to the strategic responsibility.